Volumetric Measure of the Frontal and Temporal Lobe Regions in Schizophrenia

Relationship to Negative Symptoms

Michael Sanfilipo, MS; Todd Lafargue, MD; Henry Rusinek, PhD; Luigi Arena, MD, PhD; Celia Loneragan, MA; Andrew Lautin, MD; Deborah Feiner, BA; John Rotrosen, MD; Adam Wolkin, MD

Background: Previous research has provided evidence for brain abnormalities in schizophrenia, but their relationship to specific clinical symptoms and syndromes remains unclear.

Methods: With an all-male demographically similar sample of 53 schizophrenic patients and 29 normal control subjects, cerebral gray and white matter volumes (adjusted for intracranial volume and age) were determined for regions in the prefrontal lobe and in the superficial and mesial temporal lobe using T1-weighted magnetic resonance imaging with 2.8-mm coronal slices.

Results: As a group, schizophrenic patients had widespread bilateral decrements in gray matter in the prefrontal (7.4%) and temporal lobe regions (8.9%), but not in white matter in these regions. In the temporal lobe, gray matter reductions were found bilaterally in the superior temporal gyrus (6.0%), but not in the hippocampus and parahippocampus. While there were no overall group differences in white matter volumes, widespread decrements in prefrontal white matter in schizophrenic patients (n = 53) were related to higher levels of negative symptoms (partial r[49] = −0.42, P = .002), as measured by the Scale for the Assessment of Negative Symptoms. A post hoc analysis revealed that schizophrenic patients with high negative symptoms had generalized prefrontal white matter reductions (11.4%) that were most severe in the orbitofrontal subregion (15.1%).

Conclusions: These results suggest that gray matter deficits may be a fairly common structural abnormality of schizophrenia, whereas reductions in prefrontal white matter may be associated with schizophrenic negative symptoms.

Arch Gen Psychiatry. 2000;57:471-480
SUBJECTS AND METHODS

SUBJECTS

Fifty-three male schizophrenic patients and 29 male normal controls, all recruited from the New York Veterans Affairs Medical Center, New York, gave informed consent to participate in the study. The study procedures and consent forms used received approval from the Institutional Review Boards at the New York Veterans Affairs Medical Center and New York University Medical Center. Data from this sample have been included in part elsewhere in our reports on the cerebral ventricular system and whole-brain image averaging.

Schizophrenic patients were recruited from inpatient and outpatient hospital facilities, and all met DSM-III-R criteria for schizophrenia as diagnosed by 2 psychiatrists (T.L. and A.W.) and assessment using the Structured Clinical Interview for DSM-III-R Patient Edition. Schizophrenic patients with current substance abuse (ie, last use ≤3 months) or any history of substance dependence (past or present, excluding caffeine and nicotine) were excluded from the study. Eighteen schizophrenic patients with a history of substance abuse (ie, last drug abuse >3 months) were included in the study (Table 1).

Normal control candidates, responding to a posted hospital announcement, received an initial telephone screening and then an evaluation interview, which included the Structured Clinical Interview for DSM-III-R Non-Patient Edition. Normal controls were excluded from the study if they had a first-degree family history of psychiatric illness, an educational level higher than 16 years, or any current or past DSM-III-R psychiatric or substance abuse diagnoses (excluding caffeine dependence, nicotine dependence, and prior isolated episodes of depression).

Additional exclusion criteria for all subjects included mental retardation, aged older than 50 years, any contraindications for MR imaging, any current medical illness, or any history of head trauma, loss of consciousness, seizures, neurologic disease, or central nervous system infections. Finally, 3 subjects (2 controls and 1 patient) were excluded from the study because their MR imaging scan uncovered clear evidence of a pathologic brain condition as assessed by a clinical radiologist (L.A.).

All schizophrenic patients were receiving neuroleptic medication (Table 1) at the time of the MR imaging scan for treatment of either acute or chronic decompensation of schizophrenia. Psychiatric ratings (Table 1), including the Clinical Global Impressions Scale, Brief Psychiatric Rating Scale, the Scale for the Assessment of Negative Symptoms (SANS), the Simpson-Angus Scale (for extrapyramidal symptoms), and the Abnormal Involuntary Movement Scale, were obtained when patients were clinically judged to have had an optimal response to medication, which ranged from the day of to 12 weeks after the MR imaging scan. The purpose of obtaining clinical ratings at the time of optimal medication response was to provide a more uniform comparison of psychopathology across patients who initially were seen at different stages of symptom severity.

MR IMAGING SCANS

Magnetic resonance imaging scans were obtained with a 1.5-T scanner (Vista HPQ; Picker, Cleveland, Ohio). Coronal T1-weighted images of the whole brain (perpendicular to the sylvian fissure) were acquired with a high-resolution, 3-dimensional, radiofrequency–spoiled gradient echo technique (repetition time = 33 milliseconds, echo time = 11 milliseconds, flip angle = 35°, 256 × 256-pixel acquisition matrix, 85 slices, slice thickness = 2.8 mm, no slice gap, field of view = 24 cm, and 1 signal average), which provided an excellent contrast between gray and white tissue with a short acquisition time. To determine the degree of whole-brain alignment uniformity across cases, coronal images were reformatted in the sagittal plane and, on the midsagittal slice, the angle between the horizontal and the line through the anterior and posterior commissures was measured. The mean (±SD) angle was 17.9° ± 5.3° (average error = 4.1°, reference range, 3.0°-32.0°) and was not different for the schizophrenic patients (18.3° ± 5.3°) or the normal controls (17.4° ± 5.1°).

For estimation of intracranial volume (ICV) and clinical screening of brain pathology, T2-weighted and proton density-weighted axial images of the whole brain were acquired with a 2 echo spin–echo pulse sequence (repetition time = 2400 milliseconds, echo time = 20 and 80 milliseconds, flip angle = 90°, 165 × 256-pixel acquisition matrix, 20 slices, slice thickness = 5 mm, slice gap = 1 mm, field of view = 22 cm, and 1 signal average). One individual (T.L.) performed ICV estimations for all cases by demarcating the outer boundary of the brain for each slice using automated edge-detection contour tracing. Estimations of ICV were limited to slices that ranged from the vertex to the red nuclei, as slices below could not be reliably measured.

MR IMAGING SCAN ANALYSIS

Magnetic resonance imaging scans were loaded on a personal computer system workstation (Sun, Mountain View, California), and the images were transferred to a VAX 3100 computer system (Digital Equipment Corp, Maynard, Mass) for analysis. The research group was blinded to the patient/control status of the images. The images were normalized to the midsagittal plane using the Abney normalization technique. The Abney normalization technique is based on the assumption that the midsagittal plane is a plane in which the gray matter reductions in the prefrontal region are reproducible. We also report that negative symptoms are related to white matter reductions in the prefrontal region.

RESULTS

DEMOGRAPHIC VARIABLE ANALYSES

In this all-male sample, there were no differences in age, race, and handedness between the schizophrenic and normal control groups (Table 1). These 2 groups, however, had significantly different educational levels, even though the average difference was only 1.1 years. While...
adjusted for ICV) revealed that age was inversely related to
frontal (but was unrelated to total white matter volume in the pre-
frontal and temporal regions (data not shown).

Tissue segmentation and acquisition of regions was per-
formed on the coronal T1-weighted images and included the
following steps: (1) signal intensity values for “pure” cerebrospinal fluid, gray matter, and white matter were sampled
casewise by 1 person (T.L.) from unambiguous anatomical
regions in rostral, central, and posterior portions of the brain,
in areas where partial volume effects were minimal; (2) pre-
dicted signal intensity values for gray and white matter for
each slice of each case were calculated using separate linear
regression equations (based on pure tissue samplings and
slice position), to correct for anteroposterior drift in signal
intensity values due to magnetic field inhomogeneities, head
coil artifact, and subject-induced distortions; (3) the win-
dowing threshold value for the gray vs white tissue com-
partments was defined as the midpoint between inhomoge-
neity-corrected signal intensity values for gray and white
matter for each slice; (4) 1 individual (A.W.) identified the
neuroanatomical landmarks used to define the anterior and
posterior extent of regions; (5) to obtain regions-of-
interest, rough and overinclusive outlines encircling re-
gions were manually drawn by separate single raters for the
prefrontal (T.L.) and temporal (C.L.) lobe regions, and the
resulting tracings were intersected with the inhomogeneity-
corrected signal intensity threshold value for gray or white
matter for that slice; and (6) planar regions-of-interest mea-
surements were summed across the anteroposterior extent
of each region to yield final volumetric regions. Our method
has the advantages of minimized partial volume effects,37 ac-
curate white-gray segmentation volumes,13,38 excellent in-
terscan reliability,39 and controlling for signal inhomogeneity-
artefact.37

The neuroanatomical landmarks used in our study to
delineate the amygdala, hippocampus, parahippocampus, and
superior temporal gyri were identical to those used in the
study by Shenton et al.39 In addition, volumes were
acquired for “whole” temporal gray and white matter re-
gions, which subsumed temporal lobe tissue between the
anterior and posterior boundaries for the above regions.

Subdivision of the prefrontal region was based on a geo-
metric “pie-sector” approach rather than an anatomical one,
given the difficulty in identifying specific gyri, the non-
trivial differences in intersubject cerebral shape, and the anat-
omical variability in the correspondence between location and
function. After identifying the slice anterior to the genu
of the corpus callosum, prefrontal regions-of-interest were
defined for that slice plus the 7 anterior adjacent slices (to-
tal thickness of 2.2 cm) for all study participants. For each
of the 8 prefrontal slices, MR imaging software was used to
demarcate the cortical hemispheric perimeter, calculate the
geometric centers of the left and right hemispheres, and cre-
cate 6 contiguous and nonoverlapping 60°-pie sectors for each
hemisphere that are positioned relative to the horizontal ray
extending medially from the hemispheric center (thus cre-
ating superior and inferior sets of medial, central, and lat-
eral sectors; Figure, inset). These individual sectors, com-
bed across all 8 prefrontal slices, result in 6 three-
dimensional, wedge-shaped prefrontal subregions for each
hemisphere extending in the anteroposterior plane. These
subregions are consistent in geometric location within and
between subjects and have very high reliability.

Based on the method described earlier, the intrarater
reliability for each region was determined using the same
rater on repeated identical cases (n = 5). Due to poor
intracllass correlations for the amygdala region, the results
for the amygdala were deemed unreliable and were
excluded from this study. For the remaining regions, the
average intraclass correlation coefficients were greater
than 0.99 for the prefrontal subregions (all ricc[4], >0.99,
P < .000) and 0.92 for the temporal regions (all ricc[4], >0.86,
P < .01).

**STATISTICAL ANALYSES**

All statistical analyses had a 2-tailed α level of .05 for sig-
nificance, unless otherwise stated. For the brain regions,
the analyses were performed on absolute regional white and
gray matter volumes after adjustment for ICV and age. Even
though the schizophrenic and normal control groups were
demographically similar for age, regional white and gray
matter volumes were, nevertheless, adjusted for age to re-
duce variance in the analyses, given evidence here (see “Re-
results” section) and elsewhere30 of a decrease in gray mat-
ter volume with normal aging.

An overall 3-factor group × hemisphere × region
repeated measures analysis of covariance (ANCOVA)
design adjusting for ICV and age was used as an omnibus
statistic in separate analyses for the prefrontal gray, pre-
frontal white, and temporal gray matter regions. The
omnibus ANCOVA models were followed up with
region ANCOVA designs for each of the
individual regions (adjusting for ICV and age). In addi-
tion, separate group × hemisphere ANCOVA models
(adjusting for ICV and age) were used to analyze the
whole temporal gray and white matter regions.

head circumference also was not different for these 2
groups, schizophrenic patients had a smaller ICV than
normal controls.14-23 Moreover, schizophrenic patients with
and without a history of any substance abuse did not sig-
ificantly differ for any of the prefrontal and temporal
regional volumes (data not shown).

Partial correlations (rp[df]) for the entire sample (ad-
justed for ICV) revealed that age was inversely related to
total gray matter volume in the prefrontal (rp[79] = -0.41,
P < .001) and temporal regions (rp[79] = -0.34, P = .002),
but was unrelated to total white matter volume in the pre-
frontal (rp[79] = 0.10, P = .39) and temporal lobe re-
gions (rp[79] = 0.13, P = .25). For the schizophrenic group,
total gray and white matter volume in the prefrontal and
temporal regions (after adjusting for ICV) was not signifi-
cantly related to the number of years ill, age of illness on-
set, and number of hospitalizations (data not shown).

**GROUP-REGIONAL VOLUME ANALYSES**

In the omnibus group × hemisphere × region ANCOVA
models (Table 2), the main effect of group was statisti-
cally significant for prefrontal gray matter volume
(P = .003), but was not significant for temporal gray

---

*Figure*
Table 1. Demographic and Clinical Characteristics of the 53 Schizophrenic Patients and the 29 Normal Controls*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Schizophrenic Patients</th>
<th>Normal Controls</th>
<th>Statistic</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>38.7 ± 5.5</td>
<td>35.8 ± 8.7</td>
<td>2(1, N = 82) = 640.5</td>
<td>.21</td>
</tr>
<tr>
<td>No. of years of education†</td>
<td>13.1 ± 1.8</td>
<td>14.2 ± 1.8</td>
<td>2(N = 82) = 2.48</td>
<td>.02</td>
</tr>
<tr>
<td>Race, No. of subjects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>13</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>24</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>13</td>
<td>4</td>
<td>(x^2(4, N = 82) = 7.27)</td>
<td>.12</td>
</tr>
<tr>
<td>Asian</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Handedness‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right</td>
<td>46</td>
<td>27</td>
<td>(x^2(1, N = 82) = 0.76)</td>
<td>.38</td>
</tr>
<tr>
<td>Left or mixed</td>
<td>7</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head circumference, cm</td>
<td>58.7 ± 2.2</td>
<td>58.6 ± 1.8</td>
<td>2(N = 82) = 0.20</td>
<td>.84</td>
</tr>
<tr>
<td>Intracranial volume, cc§</td>
<td>861.9 ± 91.6</td>
<td>905.3 ± 71.5</td>
<td>2(N = 82) = 2.21</td>
<td>.03</td>
</tr>
<tr>
<td>Patient status, No. of subjects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inpatients</td>
<td>26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outpatients</td>
<td>27</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schizophrenia subtype, No. of subjects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undifferentiated</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paranoid</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of years ill</td>
<td>14.4 ± 6.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age of illness onset, y</td>
<td>24.3 ± 4.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of hospitalizations</td>
<td>12.1 ± 13.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of patients receiving neuroleptic (dose range)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine (400-1200 mg/d)</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clozapine (600 mg/d)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluphenazine (15-45 mg/d)</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluphenazine decanoate (12.5-62.5 mg/2 wk)</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haloperidol (1-35 mg/d)</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haloperidol decanoate (50-300 mg/2 wk)</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesoridazine (150-300 mg/d)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olanzapine (20 mg/d)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perphenazine (16-80 mg/d)</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risperidone (6 mg/d)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thioridazine (75-500 mg/d)</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trifluoperazine (5-20 mg/d)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Substance abuse, No. of subjects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stimulant</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric rating scales, mean ± SD, score¶</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGI (1, low; 7, high)</td>
<td>4.0 ± 0.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BPRS (0, low; 6, high)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total score</td>
<td>24.3 ± 9.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schizophrenia factor#</td>
<td>6.0 ± 3.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression item</td>
<td>1.2 ± 1.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SANS (Global scores)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Affective Flattening/Blunting</td>
<td>2.6 ± 1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alogia</td>
<td>2.2 ± 0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avolition-Apathy</td>
<td>2.8 ± 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anhedonia-Asociality</td>
<td>2.7 ± 1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attention</td>
<td>1.5 ± 0.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sum of Global SANS</td>
<td>11.8 ± 3.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simpson-Angus (for EPS) total</td>
<td>2.3 ± 2.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIMS total</td>
<td>0.7 ± 1.4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Values expressed as mean ± SD, unless otherwise indicated. Probability values of significance are based on 2-tailed α level.
†Compared the educational level of parents of schizophrenic patients with the educational level of normal controls.
‡Handedness was assessed with a shortened version of the Edinburgh Inventory.
§Intracranial volumes were measured from T2-weighted axial slices ranging from the red nuclei to the vertex.
||Listed once are 2 patients receiving intramuscular and oral neuroleptic (same type) and 1 patient receiving 2 different neuroleptic drugs.
¶CGI indicates Clinical Global Impressions Scale; BPRS, Brief Psychiatric Rating Scale; SANS, Schedule for the Assessment of Negative Symptoms; EPS, extrapyramidal symptoms; and AIMS, Abnormal Involuntary Movement Scale.
#The BPRS schizophrenia factor (0, low; 6, high) measures positive symptoms and is the sum of the BPRS “conceptual disorganization,” “hallucinatory behavior,” and “unusual thought content” items.
matter volume \( (P = .06) \) and prefrontal white matter volume \( (P = .41) \). However, for the whole temporal lobe measures, the overall group \( \times \) hemisphere ANCOVA models (Table 2) revealed significant main effects for group \( (P = .001) \) and hemisphere \( (P = .03) \) in gray matter but not in white matter \( (P = .47 \) and \( P = .36 \), respectively) . All other main and interaction effects were nonsignificant, excluding the variables used as covariates. This overall pattern of results indicates that schizophrenic patients, as a group, have nonspecific reductions in prefrontal and temporal gray matter relative to normal controls, but there was no evidence for a corresponding group difference in prefrontal and temporal white matter.

The follow-up regional ANCOVA analyses (see Table 2 for group means, ANCOVA results, percentage differences, and effect sizes\(^4\)) revealed that schizophrenic patients had smaller prefrontal gray matter volumes bilaterally as compared with normal controls (with the exception of only a right hemispheric reduction in inferior central prefrontal gray matter). However, there were no group differences in white matter volume for any of the 6 prefrontal subregions. Similarly, the schizophrenic group had significant reductions in gray matter volume in the superior temporal gyrus and whole temporal cortex, but not in white matter volume in these 2 regions. In addition, laterality in regional volumes was observed in prefrontal superior lateral white matter (left>right) and in whole temporal cortex gray matter (right>left). Overall, schizophrenic patients generally had fairly large and widespread reductions in gray matter in the prefrontal (bilateral decrease of 4.89 cc \([7.4\%]\), \( d = .72 \)) and whole temporal cortex (bilateral decrease of 4.73 cc \([8.9\%]\), \( d = .80 \)) and decrements in the superior temporal cortex (bilateral decrease of 1.05 cc \([6.0\%]\), \( d = .80 \)); however, they were not different from normal controls for white matter volumes in any of the prefrontal and temporal regions.

**CLINICAL SYMPTOM–REGIONAL VOLUME ANALYSES**

Partial correlations adjusting for ICV and age were computed between bilateral regional brain volumes and the clinical ratings performed on the schizophrenic group (Table 3). After adjusting for the number of tests (2-tailed \( \alpha \) error level set to \( P < .01 \)), total prefrontal white matter was found to relate inversely to negative symptoms \( (r[p49] = -0.42, P = .002, n = 53) \), as measured by the sum of the 5 global subscales of the SANS (Figure). This relationship was a global rather than focal effect (Figure, inset), as corresponding partial correlations for the 6 individual prefrontal subregions for each hemisphere were generally robust (reference range, \( r[p49] = -0.44, P = .001 \) to \(-.25, P = .08 \)). In terms of specific negative symptoms, total prefrontal white matter was related inversely to the SANS Anhedonia-Asociality and Alogia Global subscales (Table 3). No other correlations were significant.

**POST HOC ANALYSES**

In a post hoc analysis, differences in prefrontal white matter volume were examined among normal controls and patients with low- and high-negative symptom scores (Table 4), where the high- and low-negative symptom dichotomy was based on the top quartile of the SANS (sum of global subscale scores \( \geq 16 \)). The main effect for group was significant in the omnibus analysis of the individual prefrontal subregions, in the analysis of total prefrontal volume, and for 1 individual subregion, inferior central prefrontal white matter. Follow-up t tests for these regions revealed that the high-negative symptom group had significantly smaller inferior central and total prefrontal white matter volumes than patients with low-negative symptoms and normal controls, which were not different from each other. This effect represented a bilateral reduction of 1.27 cc \([15.1\%]\), \( d = .86 \)) in inferior central white matter volume and 4.94 cc \([11.4\%]\), \( d = .75 \)) in total prefrontal white matter volume relative to the low-negative symptom schizophrenic group. (The high- and low-negative symptom schizophrenic groups were not different for any of the demographic variables listed in Table 1 [data not shown].)

**COMMENT**

In this study, we used high-resolution, 3-dimensional MR imaging to examine gray and white matter volumes in prefrontal and temporal lobe regions in an all-male, demographically similar sample of 53 schizophrenic patients and 29 normal controls. The schizophrenic group had widespread bilateral decrements in gray matter in the prefrontal and whole temporal cortex, but not in white matter in these regions. In the temporal lobe, gray matter reductions were found in superficial cortex (ie, superior temporal gyrus), but not in mesial areas (ie, hippocampus and parahippocampus). In addition, prefrontal and temporal gray matter regional volumes were unrelated to various clinical symptoms.

While there were no overall differences in white matter volumes between the schizophrenic and normal control groups, total prefrontal white matter among schizophrenic patients was inversely related to negative symptoms. For schizophrenic patients who have...
Table 2. Regional White and Gray Matter Volumes for the 53 Schizophrenic Patients and the 29 Normal Controls
After Correction for Intracranial Volume and Age

<table>
<thead>
<tr>
<th>Brain Region</th>
<th>Schizophrenic Patients</th>
<th>Normal Controls</th>
<th>Percentage of Reduction and Effect Size</th>
<th>ANCOVA F(1,78) Values and Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LH</td>
<td>RH</td>
<td>LH</td>
<td>RH</td>
</tr>
<tr>
<td></td>
<td>Group</td>
<td>Hemisphere</td>
<td>Group × Hemisphere</td>
<td>Hemisphere</td>
</tr>
<tr>
<td>Superior Medial</td>
<td>4.59 ± 0.57</td>
<td>4.86 ± 0.54</td>
<td>4.94 ± 0.58</td>
<td>5.35 ± 0.66</td>
</tr>
<tr>
<td>Prefrontal Gray</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superior Central</td>
<td>5.78 ± 0.73</td>
<td>6.08 ± 0.82</td>
<td>6.27 ± 0.74</td>
<td>6.63 ± 0.83</td>
</tr>
<tr>
<td>Prefrontal Gray</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superior Lateral</td>
<td>4.42 ± 0.60</td>
<td>4.82 ± 0.63</td>
<td>4.75 ± 0.61</td>
<td>5.31 ± 0.64</td>
</tr>
<tr>
<td>Prefrontal Gray</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inferior Medial</td>
<td>4.37 ± 0.53</td>
<td>4.81 ± 0.57</td>
<td>4.76 ± 0.54</td>
<td>5.21 ± 0.57</td>
</tr>
<tr>
<td>Prefrontal Gray</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inferior Central</td>
<td>5.26 ± 0.81</td>
<td>5.27 ± 0.84</td>
<td>5.43 ± 0.82</td>
<td>5.69 ± 0.85</td>
</tr>
<tr>
<td>Prefrontal Gray</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inferior Lateral</td>
<td>5.54 ± 0.73</td>
<td>5.66 ± 0.73</td>
<td>5.91 ± 0.74</td>
<td>6.11 ± 0.74</td>
</tr>
<tr>
<td>Prefrontal Gray</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemispheric</td>
<td>29.96 ± 3.38</td>
<td>31.49 ± 3.61</td>
<td>32.05 ± 3.42</td>
<td>34.29 ± 3.65</td>
</tr>
<tr>
<td>Prefrontal Gray</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Gray and white matter volumes were measured in cubic centimeters. Table values are the mean ± SD of absolute regional brain matter volumes after adjusting for intracranial volume (ICV) and age. F(1,78) values for each region are from a group × hemisphere (2 × 2) analysis of covariance (ANCOVA) design using ICV and age as covariates. LH indicates left hemisphere; RH, right hemisphere; SZ, patients with schizophrenia; NC, normal controls; and ellipses, not applicable.

1. Percentage reduction in regional volumes is relative to normal controls. Effect sizes (in parentheses) are group mean differences divided by the pooled SD.

2. For frontal gray matter regions, the overall group × hemisphere × region (2 × 2 × 6) ANCOVA using ICV and age as covariates had the following F values: ICV, F(2,76) = 24.58, P<.001; age, F(2,76) = 13.15, P<.001; group, F(2,76) = 9.33, P = .003; hemisphere, F(2,76) = 0.03, P = .86; region, F(2,76) = 1.41, P = .23; group × hemisphere, F(2,76) = 2.68, P = .11; group × region, F(2,76) = 1.29, P = .28; hemisphere × region, F(2,76) = 0.65, P = .67; group × hemisphere × region, F(2,76) = 0.79, P = .56.

3. For temporal lobe gray matter regions, the overall group × hemisphere × region (2 × 2 × 3) ANCOVA using ICV and age as covariates had the following F values: ICV, F(2,76) = 7.63, P<.001; age, F(2,76) = 8.82, P = .004; group, F(2,76) = 3.90, P = .06; hemisphere, F(2,76) = 0.86, P = .66; region, F(2,76) = 2.88, P = .11; group × hemisphere, F(2,76) = 0.32, P = .57; group × region, F(2,76) = 2.43, P = .08; hemisphere × region, F(2,76) = 1.49, P = .23; group × hemisphere × region, F(2,76) = 0.41, P = .67. The amygdala region was not included in the analysis due to poor reliability.

<.05; <.01; <.001; <.0001.
high-negative symptoms, reductions in total prefrontal white matter were robust relative to both schizophrenic patients who have low-negative symptoms and normal controls. This prefrontal white matter reduction was most severe in the orbitofrontal subregion. White matter volumes were not significantly correlated with age, the number of years ill, age of illness onset, and number of hospitalizations. Together, these results may indicate that gray matter deficits may be a fairly common (though not necessarily ubiquitous) structural abnormality of schizophrenia, whereas decrements in prefrontal white matter may be specifically associated with the expression of schizophrenic negative symptoms.

The results presented here are generally consistent with the extensive structural MRI imaging literature demonstrating gray matter reductions in schizophrenia in the prefrontal region, temporal lobe, and superior temporal gyrus. However, other studies, unlike our results here, have also found bilateral reductions in the hippocampus and parahippocampus. These discrepant results may be explained in part by the possibility that thin slices (thinner than 2.8 mm) are needed for detecting significant differences. The overall validity of our technique is evidenced by ratios of gray and white volumes similar to those reported in other recent studies and by the negative relationship between age and gray matter volumes, but not white matter volumes.

Of significant interest was the strong inverse relationship between schizophrenic negative symptoms and prefrontal white matter volume found in our study. Wible et al also reported such an association for white matter volume in the left prefrontal region, but did not find overall group differences in either white or gray matter. Some studies also have found that schizophrenic negative symptoms are inversely related to corpus callosum size. While most studies, like the present one, have reported no overall reductions in white matter volume in schizophrenia, some have offered evidence for reductions in total white matter absolute posterior white matter, corpus callosum, or total reductions only in nondeficit schizophrenic patients.

Additional support for white matter abnormalities in schizophrenia comes from other imaging methods, as well as from autopsy studies. Magnetic resonance spectroscopy has indicated that neuronal connections in white matter may be disrupted in schizophrenia without concomitant volumetric reductions. Widespread decreases in white matter tensor diffusion anisotropy also have been reported in schizophrenia, without evidence of volumetric white matter deficits. From postmortem data, there is cytoarchitectural evidence for an inward maldistribution of neurons in prefrontal and temporal lobe white matter regions in schizophrenia.

Autopsy evidence indicates that schizophrenia is associated with increased neuronal density in the prefrontal and other regions, which are likely to be a result of smaller neuronal cell size and overall modest cranial deficits rather than cell loss or gliosis. Sellem and Goldman-Rakic have proposed that these brain regions in schizophrenia, particularly the prefrontal cortex, may have functional impairments in the neuropil that retard synaptic interactions and cellular support activi-
ties among neuronal cells. The net result of neuropil dysfunc-
tion is impaired neural transmission, which may be worsened by possible structural abnormalities in neural pathways as a result of faulty neurodevelopment.

Given the extensive evidence for structural abnormalities in schizophrenia, especially in frontal and temporal cortical regions, support for relationships between regional brain volumes and clinical symptoms for the most part has been inconsistent, even with putative associations of positive symptoms with temporal lobe gray matter pathology. Instead of regional volumes (corresponding to localization of function), core components of schizophrenic psychopathology, such as cognitive deficits and hypofrontality, have been related to disruption in neural tracts that connect and integrate various cortical regions. In a similar fashion, “disconnection” of brain regions involving cortico-cortical and/or cortical-subcortical white matter tracks, such as those pertaining to the heteromodal association cortex, may disrupt increasingly complex human behaviors (eg, integration of volition and motivation in purposeful behavior, proper perception and expression of emotion in social interactions) and underlie the behavioral domains comprising schizophrenic negative symptoms. For example, compromised cortico-subcortical connectivity may underlie the apparent similarity between certain aspects of negative syndromes and subcortical dementia, both of which entail cognitive slowness, apathy, loss of motivation, and neurologic abnormalities. In addition, the disruption of corticolumbic (viz, amygdala) and other cortical-subcortical connections as revealed by reports of volumetric deficits in the orbitofrontal region here and elsewhere may contribute to negative symptom phenomenology.

In this study, the high-negative symptom group, while clinically stable, was defined using the top quartile of scores from the SANS, a cross-sectional phenomenological rating scale. Clearly, this clinical scale does not distinguish among various negative symptom syndromes, such as the deficit syndrome and secondary negative symptoms. However, in this study we used this straightforward assessment method because it has been associated with robust group differences in our previous functional imaging studies. For example, we have previously found a strong relationship between negative symptom severity and metabolic hypofrontality in prefrontal cortex, a finding that is possibly related to the structural results reported here.

This convergence of functional and structural results suggests that certain prefrontal abnormalities in

### Table 4. Results of the Post Hoc Analyses on Prefrontal White Matter Volumes for the High Negative Symptom, Low Negative Symptom, and Normal Control Groups After Correction for Intracranial Volume and Age

| Brain Region | With HN Symptom† (n = 13) | With LN Symptom‡ (n = 40) | Normal Controls (n = 29) | ANCOVA F1,170 Values and Results
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LH</td>
<td>RH</td>
<td>LH</td>
<td>RH</td>
</tr>
<tr>
<td>Superior Medial Prefrontal White‡</td>
<td>2.29 ± 0.75</td>
<td>2.03 ± 0.71</td>
<td>2.72 ± 0.76</td>
<td>2.24 ± 0.72</td>
</tr>
<tr>
<td>Superior Central Prefrontal White‡</td>
<td>4.21 ± 0.86</td>
<td>4.08 ± 0.75</td>
<td>4.74 ± 0.87</td>
<td>4.62 ± 0.76</td>
</tr>
<tr>
<td>Superior Lateral Prefrontal White‡</td>
<td>2.51 ± 0.60</td>
<td>2.30 ± 0.64</td>
<td>2.67 ± 0.60</td>
<td>2.72 ± 0.65</td>
</tr>
<tr>
<td>Inferior Medial Prefrontal White‡</td>
<td>3.08 ± 0.69</td>
<td>3.40 ± 0.67</td>
<td>3.29 ± 0.70</td>
<td>3.68 ± 0.68</td>
</tr>
<tr>
<td>Inferior Central Prefrontal White§</td>
<td>3.91 ± 0.81</td>
<td>3.20 ± 0.73</td>
<td>4.53 ± 0.82</td>
<td>3.84 ± 0.73</td>
</tr>
<tr>
<td>Inferior Lateral Prefrontal White‡</td>
<td>3.74 ± 0.77</td>
<td>3.48 ± 0.74</td>
<td>4.08 ± 0.78</td>
<td>4.02 ± 0.74</td>
</tr>
<tr>
<td>Hemispheric Total Prefrontal White¶</td>
<td>19.73 ± 3.52</td>
<td>18.48 ± 3.36</td>
<td>22.03 ± 3.55</td>
<td>21.12 ± 3.38</td>
</tr>
</tbody>
</table>

*Table values are the mean ± SD of absolute regional brain volume measures (in cubic centimeters) after adjusting for intracranial volume (ICV) and age. F values for each region are from a group × hemisphere (3 × 2) analysis of covariance (ANCOVA) design using ICV and age as covariates. In this design, the main effects of hemisphere, ICV, and age had df = 1, 77, and the interaction effect of group × hemisphere had df = 2, 77. Probability values of significance are based on 2-tailed α levels. LH indicates schizophrenic patients with high negative symptoms; LN, schizophrenic patients with low negative symptoms; LH, left hemisphere; RH, right hemisphere; NC, normal controls, and ellipses, not applicable.

†The high and low negative symptom schizophrenic groups were defined as patients who had total global subscale scores above and below the top quartile (≥16), respectively, on the Scale for the Assessment of Negative Symptoms (SANS). These 2 schizophrenic groups were not different for any of the demographic variables listed in Table 1 (data not shown).

‡For total prefrontal white matter regions, the overall group × hemisphere × region (3 × 2 × 6) ANCOVA using ICV and age as covariates had the following F values: ICV F[3,72] = 7.60, P = .007; age, F[3,72] = 1.05, P = .31; group, F[2,72] = 3.19, P = .05; hemisphere, F[1,72] = 2.39, P = .13; region, F[3,72] = 1.58, P = .18; group × hemisphere, F[2,72] = 0.12, P = .89; group × region, F[6,72] = 1.05, P = .15; hemisphere × region, F[1,72] = 0.63, P = .68; group × hemisphere × region, F[6,72] = 1.19, P = .30.

§For the inferior central prefrontal white matter region, the high negative symptom schizophrenic group had a bilateral reduction of 1.27 cc (15.1%, d = .86) relative to the low negative symptom schizophrenic group.

||P < .05.

¶For total prefrontal white matter volume, the high negative symptom schizophrenic group had a bilateral reduction of 4.94 cc (11.4%, d = .75) relative to the low negative symptom schizophrenic group.
schizophrenic patients may be associated with a common pathway for the expression of and/or vulnerability to various types of negative symptom syndromes, rather than an etiologically homogeneous negative syndrome. This pathway or vulnerability may result in, for instance, the mediation of secondary negative symptoms under certain conditions of neurotransmitter imbalance (ie, parkinsonism), or underlie the evolution of primary negative symptoms and the deficit syndrome during the course of schizophrenic illness.

The limitations of our study include the thickness of our MR slices (and possible type II error for certain limbic regions), correction for magnetic field inhomogeneity in only one dimension, the use of an all-male sample, the lack of prospective matching with respect to our groups, and elucidation of the negative symptom findings using exploratory post hoc analyses. Our results need to be replicated in future studies using samples of male and female patients with varying degrees and types of negative symptoms. Additional investigations with first-onset schizophrenic patients may provide clues about the time point at which prefrontal white matter deficits emerge over the course of the illness.

In summary, schizophrenic patients had widespread bilateral reductions in gray matter volume in the prefrontal and whole temporal regions, circumscribed gray matter deficits in the superior temporal gyrus, but no significant decrease in prefrontal and temporal white matter volume. However, decrements in prefrontal white matter volume were strongly associated with greater negative symptoms in schizophrenic patients.

Accepted for publication January 19, 2000.

This study was supported by the Department of Veterans Affairs, Washington, DC.

We also thank Douglas Harris, Julius Perry, and John Asarian for their assistance with acquiring the magnetic resonance imaging scans.

Corresponding author: Adam Wolkin, MD, Mental Health Service (11M), Room 17017W, Veterans Administration New York Harbor Health Care System, 423 E 23rd St, New York, NY 10010-5050 (e-mail: adam.wolkin@med.va.gov).

REFERENCES
